Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.1938 -0.0262 (-11.91%)
Streaming Delayed Price Updated: 1:53 PM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all the latest news traders need to know about! 
Via InvestorPlace
News headline image
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
News headline image
A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next ↗
Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial... 
Via Benzinga
News headline image
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
US Stocks Mostly Higher; Dow Rises 75 Points ↗
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose... 
Via Benzinga
News headline image
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
News headline image
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets ↗
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
News headline image
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
News headline image
SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds ↗
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
News headline image
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compounds 
From SciSparc Ltd
Via GlobeNewswire
News headline image
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US ↗
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications... 
Via Benzinga
News headline image
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
From SciSparc Ltd
Via GlobeNewswire
News headline image
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead ↗
(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
News headline image
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results ↗
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained... 
Via Benzinga
News headline image
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
News headline image
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
News headline image
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When ↗
(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
News headline image
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains ↗
(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction 
Via Benzinga
News headline image
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction ↗
(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to... 
Via Benzinga
News headline image
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem. 
Via Benzinga
News headline image
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.